Three-Year Real-World Outcomes of Switching to Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration
Korean Journal of Ophthalmology · 04.11.2026
DOI: 10.3341/kjo.2026.0051 ↗Kurz gefasst
Fachartikel in der Zeitschrift Korean Journal of Ophthalmology, online erschienen am 04.11.2026. Verfasst von Sooyeon Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology, Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea.
- Department of Ophthalmology, Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea. ckseek@schmc.ac.kr.
Zitieren
APA
Lee, S., Sun, H. J., Lee, S. J., & Choi, K. S. (2026). Three-Year Real-World Outcomes of Switching to Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration. Korean Journal of Ophthalmology. https://doi.org/10.3341/kjo.2026.0051
Vancouver
Lee S, Sun HJ, Lee SJ, Choi KS. Three-Year Real-World Outcomes of Switching to Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration. Korean Journal of Ophthalmology. 2026. doi:10.3341/kjo.2026.0051
BibTeX
@article{Lee2026,
author = {Lee, Sooyeon and Sun, Hae Jung and Lee, Sung Jin and Choi, Kyung Seek},
title = {Three-Year Real-World Outcomes of Switching to Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration},
journal = {Korean Journal of Ophthalmology},
year = {2026},
doi = {10.3341/kjo.2026.0051}
}
EUVIMED